"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 9 | 9 |
| 1997 | 0 | 13 | 13 |
| 1998 | 0 | 9 | 9 |
| 1999 | 0 | 10 | 10 |
| 2000 | 0 | 15 | 15 |
| 2001 | 0 | 20 | 20 |
| 2002 | 0 | 13 | 13 |
| 2003 | 1 | 22 | 23 |
| 2004 | 0 | 27 | 27 |
| 2005 | 0 | 21 | 21 |
| 2006 | 0 | 23 | 23 |
| 2007 | 0 | 17 | 17 |
| 2008 | 0 | 32 | 32 |
| 2009 | 0 | 29 | 29 |
| 2010 | 1 | 43 | 44 |
| 2011 | 0 | 40 | 40 |
| 2012 | 0 | 54 | 54 |
| 2013 | 0 | 36 | 36 |
| 2014 | 0 | 56 | 56 |
| 2015 | 1 | 48 | 49 |
| 2016 | 0 | 50 | 50 |
| 2017 | 0 | 61 | 61 |
| 2018 | 0 | 37 | 37 |
| 2019 | 0 | 34 | 34 |
| 2020 | 0 | 11 | 11 |
| 2021 | 1 | 14 | 15 |
| 2022 | 0 | 17 | 17 |
| 2023 | 0 | 10 | 10 |
| 2024 | 0 | 13 | 13 |
| 2025 | 0 | 7 | 7 |
| 2026 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 11; 336(6):464-472.
-
Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA). JCO Glob Oncol. 2026 May; 12(5):e2500287.
-
Multi-modal AI for comprehensive breast cancer prognostication. Nat Commun. 2026 May 20; 17(1).
-
Hematolymphoid neoplasms involving the breast: A single institution clinicopathologic study of 59 patients. Ann Hematol. 2026 Apr 10; 105(5).
-
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 May 10; 44(14):1283-1295.
-
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025 Dec 01; 117(12):2643-2652.
-
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer. Ann Oncol. 2025 11; 36(11):1356-1365.
-
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer. J Urol. 2026 01; 215(1):44-56.
-
Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease-Free Survival. Biom J. 2025 08; 67(4):e70064.